Study type: In vitro · Status: Verified against declared source
Design, Recombinant Fusion Expression and Biological Evaluation of Vasoactive Intestinal Chemical sequence Analogue as Novel Antimicrobial Agent.
Molecules (Basel, Switzerland) · 2017
Study scale: Not reported
Abstract only: Open source record
Product or molecular entity relationships
- VIP: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.
Plain-language verified summary
Question
In the present study, we aimed to design and generate a novel peptide (VIP analogue) with an enhanced antimicrobial potency, low or no-haemolytic activity, and high stability by amino acid substitution based on their physicochemical property and usual antimicrobial mechanism, and establish an effective and low-cost production method by fusion expression of VIP analogue with Trx in E.
Methods
However, up to now, VIP has not been widely used in agriculture, food or medicine because of the following shortcomings: (1) relatively low antimicrobial activity compared with the classical antibiotics; (2) instability and extreme sensitivity to the peptidases present in body after systemic administration; (3) purification of the natural VIP or artificial synthesis of VIP is low efficient or expensive [10,11].
Scale or participants
Not reported in the reviewed source.
Key findings
Antimicrobial peptides represent an emerging category of therapeutic agents with remarkable structural and functional diversity.
Limitations and uncertainty
However, up to now, VIP has not been widely used in agriculture, food or medicine because of the following shortcomings: (1) relatively low antimicrobial activity compared with the classical antibiotics; (2) instability and extreme sensitivity to the peptidases present in body after systemic administration; (3) purification of the natural VIP or artificial synthesis of VIP is low efficient or expensive [10,11].
Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.